Quantitation of Diclofenac, Tolbutamide, and Warfarin as Typical CYP2C9 Substrates in Rat Plasma by UPLC-MS/MS and Its Application to Evaluate Linderane-Mediated Herb-Drug Interactions

Figure 5

Plasma concentration–time curves of warfarin in treated group and control group. Six rats in each group were intragastrically given 20 mg/kg of LDR (treated group) or identical volume of 0.5% CMC-Na (control group) for fifteen consecutive days, respectively. The two groups were intragastrically given warfarin prepared in 0.5% CMC-Na at a dose of 2 mg/kg at the sixteenth day.